Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tianyin Pharma Creates New Antibiotic JV

publication date: Oct 30, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Tianyin Pharmaceutical has formed a joint venture with Sichuan Mingxin Pharmaceutical Co. to produce macrolide antibiotics, such as azithromycin, clarithromycin and roxithromycin. Tianyin will own 77% of the JV, which will be known as Sichuan Jiangchuan Pharmaceutical Co., Ltd. Although Tianyin was historically focused on TCM products, it received its first SFDA approval for an antibiotic, Azithromycin Dispersible Tablets, in 2008. More details...

Stock Symbol: (NYSE Alternext: TPI)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners